Blockchain Registration Transaction Record

Annovis Bio Regains NYSE Compliance, Advances Neurodegeneration Drug

Annovis Bio regains NYSE compliance, continuing trading under ANVS. The biotech advances buntanetap for Alzheimer's and Parkinson's diseases, targeting neurotoxic proteins to halt neurodegeneration.

This news matters because it ensures that Annovis Bio can continue trading on the NYSE, maintaining liquidity and visibility for investors. The company’s drug candidate, buntanetap, targets multiple neurotoxic proteins implicated in Alzheimer’s and Parkinson’s diseases, offering a potential disease-modifying therapy for millions of patients worldwide. Regaining NYSE compliance also signals financial stability, which is critical for a clinical-stage biotech to fund ongoing Phase 3 trials and bring innovative treatments to market.